Basel, Switzerland,Dec.11, 2025. Allegria Therapeutics (ALLEGRIA), a Swiss biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, announced today the successful completion of a USD 5.1 million seed extension financing.

The financing round was led by ALK Abelló, with participation of HighLight Capital (HLC), Lichtsteiner Foundation and co-founding investor Forty51 Ventures.

The investment sets the stage for accelerated growth and value creation for ALLEGRIA. The funds will be used to progress its lead program towards pre-clinical candidates in support of nomination its first clinical candidate, while at the same time meaningfully advancing its discovery-stage programs.

ALLEGRIA was founded in 2023. Since its inception, the company has established a highly experienced specialist core team and advisory board. ALLEGRIA is progressing a differentiated portfolio of proprietary therapeutic approaches and targets to selectively modulate mast cells. By leveraging its unique insights and strategy, it has identified differentiated molecules that have great promise for the development of transformative therapies with first-in-class and best-in-disease potential for the treatment of patients with allergies and related inflammatory conditions.

“Precision approaches offer the ability to target defined cell types and pathways to disrupt the pathogenic biology driving disease with optimal efficacy and safety” says Maria van Dongen, Ph.D., Co-founder and CEO. “By identifying the relevant pathways and targets in uncontrolled mast cell activation, and leveraging our extensive experience in drug development, we aim to bring more and better options to patients across numerous allergic and inflammatory diseases. The current financing round importantly supports us in that journey.”